Chapter 19 Quiz — The Gray Market

Twenty-two items. A mix of multiple choice, true/false with justification, and short answer. The answer key is collapsed at the bottom; the questions are worth more than the key, so resist for a few minutes.

1. In pharmaceutical manufacturing, "release" refers to:

  • A. The moment a batch leaves the factory loading dock
  • B. A documented decision by a qualified person that a batch conforms to a written specification
  • C. The publication of a certificate of analysis
  • D. Regulatory approval of the drug

2. True or false, with one sentence of justification: A vial of peptide that has passed a sterility test cannot cause a fever.

3. Endotoxins are best described as:

  • A. Living bacteria that survive freeze-drying
  • B. Toxic byproducts of peptide synthesis
  • C. Lipopolysaccharide fragments of Gram-negative bacterial cell walls
  • D. Residual solvents left over from purification

4. Which of the following is not one of the six independent quality questions in §19.3?

  • A. Identity
  • B. Bioavailability
  • C. Endotoxin
  • D. Residuals

5. A deletion sequence arises when:

  • A. A vendor removes a residue to avoid a patent
  • B. A coupling step fails and the chain continues growing without that residue
  • C. A peptide is degraded by proteases after manufacture
  • D. Lyophilization removes a terminal amino acid

6. Short answer: State the difference between purity and peptide content, and explain why a product can be honestly labeled and still contain less peptide than a buyer expects.

7. True or false, with justification: A certificate of analysis establishes what is in the vial you are holding.

8. The phrase "for research use only, not for human consumption" primarily accomplishes which of the following?

  • A. It guarantees the material was made to a laboratory standard
  • B. It places the product outside the regulatory definition of a drug by attaching no therapeutic claim
  • C. It signals that the material is unsafe
  • D. It exempts the seller from all legal liability in all jurisdictions

9. "Epistemic laundering" describes:

  • A. A vendor falsifying a certificate of analysis
  • B. A therapeutic claim assembled across several parties, none of whom individually made it
  • C. The deliberate removal of impurities from a peptide preparation
  • D. Regulators reclassifying a substance to permit its sale

10. Aggregation matters primarily because:

  • A. It reduces potency proportionally
  • B. It makes the solution visibly cloudy so the problem is easy to detect
  • C. Aggregated peptide is substantially more immunogenic than properly formulated peptide
  • D. It causes the peptide to precipitate out of the vial entirely

11. Short answer: Explain, in two sentences, why anti-drug antibodies that cross-react with an endogenous peptide represent a different category of harm from a drug simply losing effect.

12. Which statement about compounded products is correct?

  • A. 503B products are FDA-approved; 503A products are not
  • B. Neither 503A nor 503B compounded products are FDA-approved or reviewed for safety and efficacy
  • C. Both are reviewed for efficacy but not for safety
  • D. Compounded products are approved once a shortage is declared

13. True or false, with justification: Semaglutide sodium and semaglutide are the same substance under different names.

14. The dosing errors reported during the compounded semaglutide episode arose principally from:

  • A. Deliberate mislabeling by compounders
  • B. A wrong molecule being supplied
  • C. Substitution of a vial-and-syringe format for an engineered delivery device
  • D. Contamination of the drug substance

15. §19.4 declines to state what proportion of gray-market products fail testing. The best reason is:

  • A. The data are proprietary
  • B. Sampling is non-random, test panels differ, and there is no denominator
  • C. Testing methods are not accurate enough to detect failures
  • D. Regulators have prohibited publication of the figures

16. Short answer: A survey of unregulated products checks identity, purity, and content, and reports that most samples were acceptable. Name the most important thing a reader should not conclude, and why.

17. Which of the following does medical supervision provide that self-directed research cannot?

  • A. A baseline measurement taken before exposure began
  • B. A differential diagnosis when a new symptom appears
  • C. Someone with the standing to say stop
  • D. All of the above

18. True or false, with justification: If a compound's effect is fading, the appropriate inference is that the dose has become insufficient.

19. "Absence of reported harm is close to uninformative" in the gray market because:

  • A. Users are dishonest about their experiences
  • B. No reporting pathway exists, so the absence of reports reflects the absence of collection
  • C. Adverse events from peptides are always immediately obvious
  • D. Regulators suppress the reports they receive

20. Chapter 3's cadaver growth hormone case is used in this chapter mainly to illustrate:

  • A. That natural substances are safer than synthetic ones
  • B. That growth hormone is inherently dangerous
  • C. That a long-latency harm was detectable only because records existed
  • D. That regulators act too slowly

21. Short answer: In the World Anti-Doping Code, why can a compound be prohibited in competition without appearing on the Prohibited List by name?

22. Short answer: State the chapter's closing position in one sentence, and name the word that carries the risk in that sentence.

Answer key **1. B.** Release is a documented decision by a named qualified person comparing batch results against a written specification. It is what converts material into a product and creates the traceability a recall depends on. (§19.1) **2. False.** Sterility asks whether anything is alive in the vial; endotoxin asks whether anything ever was. Endotoxin survives sterilization, is not removed by sterilizing filtration, and produces fever and inflammatory responses when injected — so a perfectly sterile batch can be heavily contaminated with it. (§19.3) **3. C.** They are molecular debris from the outer cell wall of Gram-negative bacteria, not organisms, which is exactly why killing the organisms does not remove them. (§19.3) **4. B.** Bioavailability is a pharmacokinetic property, not one of the six quality attributes. The six are identity, purity, content, sterility, endotoxin, and residuals. (§19.3) **5. B.** Solid-phase synthesis adds one residue at a time; when a coupling fails on some fraction of chains, those chains keep growing, permanently short one residue. The product is nearly identical in mass and chromatographic behavior, which is what makes it hard to remove and hard to see. (§19.3) **6.** Purity describes what fraction of the *peptide-like material* present is the intended molecule. Peptide content describes what fraction of the *total mass* in the vial is peptide at all — the rest being bound water and counterions from purification. A product labeled by gross weight can therefore be entirely honest and contain meaningfully less peptide than the number on the label implies, unless content has been determined and accounted for. (§19.3) **7. False.** A certificate is a report of tests performed on a *sample*. It may describe a different batch, may have originated several handling steps upstream, or may have no relationship to your container. It is a claim about a sample, not a property of a vial. (§19.3, Chapter 34) **8. B.** A drug is defined substantially by intended use. Removing the therapeutic claim changes the regulatory object without changing the molecule. It also does liability work, but it guarantees nothing about quality — research-use material is released against research specifications. (§19.2) **9. B.** The vendor sells a reagent, the forum shares experiences, the commentator describes what people do, the clinic advertises in general terms. Each element is individually defensible; the assembly is the claim. (§19.2) **10. C.** The intuitive model — that a mishandled vial simply lost potency — is wrong in kind. Aggregated peptide is presented to the immune system as a repetitive, multivalent assembly and is substantially more immunogenic. Mishandling changes the risk profile, not just the strength. Note also that an aggregated solution can look perfectly clear. (§19.3) **11.** A neutralized drug stops working, which is a treatment failure. Antibodies that cross-react with the corresponding endogenous molecule can interfere with the body's own physiology, which is a harm that persists independently of the drug and does not necessarily resolve on stopping. (§19.3) **12. B.** Neither category is FDA-approved. Regulatory attention in compounding is directed at how the product is made, not at whether it works or is safe for the intended purpose. 503B facilities operate to a substantially higher manufacturing standard than 503A, and that is a separate matter from approval. (§19.5) **13. False.** A salt form is a different chemical entity from the base. The safety and efficacy data supporting the approved product were generated with semaglutide base, and evidence does not transfer automatically across salt forms — the transfer has to be demonstrated. (§19.5) **14. C.** No molecule changed and no seller lied. The approved product is a pre-filled pen delivering fixed increments; a vial-and-syringe format transfers the measurement task to the patient. The failure mode was introduced by the format. (§19.5) **15. B.** Products get tested because someone was suspicious or because they were easy to obtain; panels vary so "pass rates" are not comparable; and nobody knows the size of the population. The honest summary is that failures occur in every category and the rate is not knowable. (§19.4) **16.** That the products were suitable for injection. Sterility and endotoxin were not in that analysis, and the absence of a failure you did not test for is not a pass. The reasonable reading is narrower: most samples contained approximately the right peptide. (§19.4) **17. D.** All four items named — baseline, differential diagnosis, standing to say stop, plus the other four in §19.7 — are things a clinical relationship supplies and reading does not. Note the chapter's boundary: testing a product and monitoring yourself do not substitute for supervision. (§19.7) **18. False.** The effect may be fading because receptors have desensitized and downregulated under sustained stimulation. If so, increasing the dose deepens the desensitization while raising exposure. The intuitive response is the opposite of the correct one, and distinguishing the two situations requires knowledge that feeling does not provide. (§19.7, Chapter 2 §2.8) **19. B.** There is no manufacturer of record, no spontaneous reporting channel for the product, no signal detection, and no recall pathway. Compounding this, the failure modes that matter most — endotoxin reactions, wrong content, immunogenicity, long-latency harm — do not produce events anyone would attribute to a product even if a channel existed. (§19.8) **20. C.** The harm had an incubation period measured in years to decades and was identified only because national programs kept records of who received which batch. In an undocumented market the same contamination would have produced scattered tragedies with no visible common cause. Note also that the substance was entirely natural and human-derived, which is the setup for §19.10. (§19.8) **21.** The Prohibited List includes a non-approved substances category covering any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. That captures most research peptides by definition, without naming them. Combined with strict liability, an unverified vial is a career risk independent of any health risk. (§19.9) **22.** *This chapter is not anti-peptide; the risk word is* **unregulated**, *not* **peptide**. What predicts the safety of a preparation is what is in it, how it was made, what could have contaminated it, and whether anyone checked — not whether the molecule is synthetic or natural, and not whether the compound is promising. (§19.10)